Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(19 sites)
China
The Second Xiangya Hospital Of Central South University, Changsha, Changsha The First Affiliated Hospital of PLA Army Medical University, Chongqing, Chongqing Municipality The Third Affiliated Hospital,Sun Yat Sen University, Guangzhou, Guangdong Peking University Shenzhen Hospital, Shenzhen, Guangdong The Second Affiliated Hospital of Harbin Medical University, Harbin, Harbin Xiangya Third Hospital, Central South University, Changsha, Hunan The First Affiliated Hospital of Baotou Medical College, Baotou, Inner Mongolia Zhongda Hospital Southeast University, Nanjing, Jiangsu The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai Municipality The First Affiliated Hospital of Medical college of Xi'an Jiaotong University, Xian, Shanxi Sichuan Province People's Hospital, Chengdu, Sichuan Second Hospital of Shanxi Medical University, Shanxi, Taiyuan The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang The first affliated hospital of NingBo university, Ningbo, Zhejiang Taizhou Hospital of Zhejiang Province, Taizhou, Zhejiang Peking University First Hospital, Beijing